At a glance
- Originator Merck & Co
- Class Antibacterials
- Mechanism of Action Deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 15 Jun 2001 No-Development-Reported for Gram-negative infections in USA (Parenteral)
- 12 May 1997 New profile
- 12 May 1997 Preclinical development for Gram-negative infections in USA (Parenteral)